Search results
Results from the WOW.Com Content Network
The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.
Can tinkering around the edges actually make this stock more attractive?
Shares of Kenvue were priced at $22, [21] [22] [23] implying an initial equity valuation for Kenvue of about $41 billion, and traded at $26.90 at the end of the first trading day. [24] Raising about $3.8 billion in capital for Kenvue, it was the largest IPO since the IPO of Rivian on November 10, 2021. [25]
Kenvue expects full-year 2024 adjusted EPS of $1.10-$1.20 versus consensus of $1.14. Price Action: KVUE stock is up 13.80% at $20.70 at the last check on Tuesday. Read Next:
Kenvue forecast 2024 adjusted profit of $1.10 to $1.20 per share, compared with estimates of $1.26.The company also missed Street estimates for fourth-quarter sales in both its self-care, as well ...
Howard Lindzon is a Canadian Author, financial analyst, technical analyst and super angel investor. Lindzon manages a hedge fund, serves as managing partner of the holding company Social Leverage, limited partner at Knight's Bridge Capital Partners, and is the co-founder of StockTwits.
The name, pronounced ken-view, comes from the English word "ken," which is primarily used on Scotland and means knowledge, and "vue," which references sight. Kenvue, which will become a standalone company in 2023, will include in its portfolio brands such as Band-Aid, Aveeno, Listerine, Tylenol and Neutrogena. [citation needed]
In Kenvue, our Chief Growth Officer, Charmaine England, is leading the segment in interim and making great progress there. I talked about how the U.S. team is focused on execution. The same thing ...